Inventiva Pharma
- Company typePublic
- Founded2012
- HeadquartersDaix, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Inventiva Pharma firmographics
Firmographics- Name
- Inventiva Pharma
- Legal name
- Inventiva S.A.
- Website
- https://inventivapharma.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Inventiva Pharma industry classification
Industry- Product category
- MASH Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industries
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where Inventiva Pharma is headquartered
LocationHeadquarters
- HQ city
- Daix
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Inventiva Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Licensing and milestone revenues: Inventiva generates revenue through licensing agreements with partners, including milestone payments from CTTQ/Sino Biopharm for China development and Hepalys Pharma for Japan/South Korea. The company reported revenues of €4.5 million in 2025 (down from €9.2 million in 2024), primarily from licensing agreement milestones.
- Future product sales (pre-commercial): Inventiva is pre-commercial, with lanifibranor in Phase 3 development. Upon regulatory approval, the company plans to commercialize lanifibranor for MASH treatment, targeting a projected market of $24 billion by 2035 according to analyst estimates.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Inventiva Pharma product offering
Product offeringCore offering
Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an oral pan-PPAR agonist therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The drug simultaneously targets the three core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis in a single oral investigational therapy. Lanifibranor is currently completing a global pivotal Phase 3 NATiV3 clinical trial following positive Phase 2b NATIVE results, with FDA Breakthrough Therapy and Fast Track Designations supporting expedited regulatory review.
Product overview
Inventiva Pharma is a clinical-stage biopharmaceutical company developing a novel oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's primary product candidate is lanifibranor, an oral pan-PPAR agonist that simultaneously targets the core biological drivers of MASH: metabolic dysfunction, inflammation, and fibrosis. The company is advancing lanifibranor through a global Phase 3 clinical trial (NATiV3) following positive Phase 2b results. Inventiva has received Breakthrough Therapy and Fast Track designations from the FDA for lanifibranor.
Differentiator
Problem solved
Functional benefit
Products and services
- Lanifibranor Oral pan-PPAR (peroxisome proliferator-activated receptor) agonist investigational therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH), targeting metabolic dysfunction, inflammation, and fibrosis simultaneously in a single oral therapy. Currently in Phase 3 NATiV3 clinical development following positive Phase 2b NATIVE results.
Quantifiable outcome
- Phase 2b NATIVE trial demonstrated improvements in liver fibrosis and MASH resolution
- +2 more outcomes
Companies that use Inventiva Pharma
Customer profileSegments1 record
Ideal customer profiles3 records
Inventiva Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Inventiva Pharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, regional and minor.
- CTTQ (Sino Biopharm subsidiary)coreInventiva received $10 million milestone payment from CTTQ following successful financing and clinical trial progress. CTTQ holds license for lanifibranor development and commercialization in China. Sino Biopharm received NMPA IND approval for clinical development in China.
- Hepalys Pharma, Inc.regionalInventiva and Hepalys Pharma signed exclusive license agreement to develop and commercialize lanifibranor in Japan and South Korea. First participant included in Phase 1 study in Japan.
- EchosensminorInventiva and Echosens launched joint initiative to raise awareness about NASH and facilitate access to screening for at-risk patients.
- AbbVieminorInventiva partnered with AbbVie for development of cedirogant (ABBV-154), an RORγ agonist for autoimmune diseases including psoriasis. Inventiva received $4 million milestone payment following initiation of Phase IIb study.
- Sino BiopharmcoreInventiva and Sino Biopharm signed licensing and collaboration agreement to develop and commercialize lanifibranor in China. Includes potential milestone payments and royalties based on development and sales progress.
Scale indicators11 records
Recent moves5 records
Expansion highlights4 records
Inventiva Pharma competitors and assessment
Company assessmentBroad incumbents
- Novo Nordisk: Global leader in diabetes/obesity with semaglutide (Wegovy/Ozempic) advancing through Phase 3 in MASH; broad metabolic disease incumbent that competes for the same MASH patient population.
- Eli Lilly: Large pharmaceutical company whose tirzepatide (Mounjaro/Zepbound) and retatrutide are demonstrating strong MASH efficacy in Phase 3; broad metabolic disease incumbent that pressures the addressable market for lanifibranor.
- Pfizer: Large pharmaceutical company with active MASH pipeline programs and significant commercial infrastructure; relevant incumbent peer and potential acquirer of differentiated late-stage MASH assets like lanifibranor.
Direct peers
- NGM Biopharmaceuticals: Clinical-stage biotech with MASH programs (formerly aldafermin and related metabolic liver assets); comparable small-cap hepatology R&D profile to Inventiva.
- Terns Pharmaceuticals: Developing TERN-501 (oral THR-β agonist) for MASH; small-cap clinical-stage peer pursuing differentiated oral MASH mechanism similar to lanifibranor's positioning.
- Viking Therapeutics: Clinical-stage biotech developing VK2809 (oral thyroid receptor beta agonist) for MASH and VK2735 for obesity; pursues overlapping metabolic liver disease indications with lanifibranor.
- Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH; competes with lanifibranor in the advanced fibrosis MASH segment with Phase 3 HARMONY data.
- 89bio: Developing pegozafermin, a long-acting FGF21 analog for MASH with positive Phase 2b/3 data; directly comparable to lanifibranor as a late-stage MASH-focused biotech.
- Madrigal Pharmaceuticals: Developer of resmetirom (Rezdiffra), the first FDA-approved oral therapy for MASH with moderate-to-advanced fibrosis; direct late-stage competitor to lanifibranor in the same MASH indication.
- Galmed Pharmaceuticals: Clinical-stage developer of aramchol for MASH; small-cap MASH-focused peer with similar profile to Inventiva as a single-asset hepatology biotech.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Inventiva Pharma social profiles
Digital presenceInventiva Pharma compliance and trust
Trust signalCompliance1 record
Inventiva Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inventiva Pharma leadership team
Management profileNumber of profiles
Profiles10 records
Inventiva Pharma funding detail
Funding detailFunding overview
Funding rounds15 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inventiva Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inventiva Pharma
What does Inventiva Pharma do?
Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an oral pan-PPAR agonist therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The drug simultaneously targets the three core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis in a single oral investigational therapy. Lanifibranor is currently completing a global pivotal Phase 3 NATiV3 clinical trial following positive Phase 2b NATIVE results, with FDA Breakthrough Therapy and Fast Track Designations supporting expedited regulatory review.
Is Inventiva Pharma a public or private company?
Inventiva Pharma is a public company. It is classified as public and is currently operating.
When was Inventiva Pharma founded?
Inventiva Pharma was founded in 2012. It employs 101 to 250 people.
Where is Inventiva Pharma based?
Inventiva Pharma is headquartered in Daix, France, in the Europe region.
How does Inventiva Pharma make money?
Two revenue lines are on record. Licensing and milestone revenues are the primary driver. The others are future product sales (pre-commercial).
Who are Inventiva Pharma's main competitors?
Broad incumbents on record are Novo Nordisk, Eli Lilly and Pfizer. Direct peers are NGM Biopharmaceuticals, Terns Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, 89bio, Madrigal Pharmaceuticals and Galmed Pharmaceuticals.
Does Inventiva Pharma have an API?
No public API is recorded for Inventiva Pharma.
What industry is Inventiva Pharma in?
Inventiva Pharma's product category is MASH Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.